Sanofi SNY
Price chart
Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.
Community Sentiment on SNY
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
Strategy Backtest
Pick a strategy above and run the backtest to see its simulated performance on SNY.
Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.
SNY at a glance
Sanofi stock (SNY) sits at $47.04, up 0.28% today. The business is worth $112.71B in the market, good for #181 of 3753 on our coverage list.
Over a full year the shares have ranged across $39.07 to $49.91, which puts the current price roughly 73% of the way up that band. Holders are behind 0.0% over twelve months, but up 8.2% across the last three months.
On the chart it holds above both the 50-day ($42.30) and 200-day ($43.48) moving averages; RSI is 73, which some call overbought, and the last 30 sessions moved at roughly 28% annualized volatility.
For the quarter ended Sep 2026 it reported €15.23B in revenue, up 15.7% from a year earlier, with €3.03B of net profit (a 8.2% margin).
The stock changes hands at 24.1 times trailing earnings, 36% above its five-year average of 17.8. The median for its industry group is 19.3.
1 analysts follow the stock and the average call is "hold". The mean target, $57.00, sits 21.2% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
BeStock Grade
Composite of 4 factors below, ranked against the 3741 U.S. stocks BeStock covers.
Cheaper than usual on its own 5-year P/E history scores higher.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
1 analysts, consensus Hold.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
BeStock Momentum
SNY is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2020-12-28, the strategy has returned 437.6% (203.8% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.
Price forecast
What Wall Street analysts and Morningstar's fair-value model expect for the stock
Wall Street’s average 12-month target is $57.00, 21.2% above today’s price, with a consensus rating of Hold. Morningstar’s fair value model puts the stock at $54.39, so shares trade 13.5% below that estimate. On earnings multiple, it sits in the 84th percentile of its own five-year valuation range (pricier than usual).
Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.
Sanofi: the business
Sanofi is a French drugmaker with major vaccine and immunology businesses, notably Dupixent, and consumer health products.
What tends to move it. Dupixent sales growth and the progress of its next-generation drugs are the most-watched items.
Where the case gets weaker. Slowing Dupixent sales growth would remove the main driver behind Sanofi's recent strong performance, and any delay or disappointing trial result in its next-generation pipeline would leave fewer catalysts to offset that loss over time.
Written by hand by the BeStock desk and revised when a business changes. how we work. Spot something out of date? Tell us.
Performance
Price return over each window, from adjusted daily and weekly closes
Technical signals
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +10.6% | Bullish |
| Price vs 50-day average | +11.2% | Bullish |
| Price vs 200-day average | +8.2% | Bullish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 73.2 | Neutral |
| MACD (12,26,9) | 1.42 | Bullish |
| Bollinger band position | 92% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Key statistics
Quote as of Nov 7, 2026 9:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.
How SNY ranks on BeStock
Ranks are among the 3,741 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Set against the peer table: at 24.1x earnings, SNY looks cheap against the market, and trades 25% above the 19.3x median among Drug Manufacturers - General names. The two comparisons do not always agree.
SNY stock: common questions
What is SNY's latest share price?
$47.04 is the latest print for SNY, a move of +0.28% against yesterday's close of $46.91. Today's low and high so far: $45.58 and $47.16.
How large is Sanofi by market value?
Equity value comes to $112.71B at the current price. By that measure it is number 181 of the 3753 names in our coverage.
How is Sanofi valued against its profits?
Buyers pay 24.1 times the last twelve months of profit (EPS $3.57). Averaged over five years the multiple has been 17.8, and today's level ranks in the 84th percentile of its own history.
How far is SNY from its yearly high?
The year's floor is $39.07 and the ceiling $49.91. Shares are 5.8% away from that ceiling.
Are there dividends on Sanofi shares?
It does. Payouts over the past twelve months work out to a 4.99% yield; the latest ex-dividend date was May 4, 2026.
What is the analyst view on Sanofi?
Of 1 analysts, 0% say buy, 100% hold and 0% sell. Price targets average $57.00, with the most cautious at $57.00 and the most optimistic at $57.00.
What does Sanofi do?
Sanofi is a French drugmaker with major vaccine and immunology businesses, notably Dupixent, and consumer health products.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on SNY.
Sign in to join the discussion.